TriLink BioTechnologies® and Intellia Sign Multiyear Supply Agreement
SAN DIEGO –TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and a recognized leader in the production of high-quality nucleic acid-based products, today renews a multi-year supply agreement with Intellia Therapeutics, a pioneering genome editing company.
This agreement ensures the consistent provision of products for messenger RNA (mRNA) manufacturing, including certain cap analogs. Both companies recognize the transformative potential of mRNA technologies and are resolute in their endeavor for groundbreaking innovations in human health.
"We are thrilled to continue our relationship with Intellia Therapeutics, a leader in genome editing. This renewed agreement underscores our mutual commitment to harnessing the revolutionary capabilities of mRNA technologies,” shared Trey Martin, CEO of Maravai LifeSciences. “We aim not only to meet the demands of today but also to pioneer the therapies of tomorrow. TriLink’s unique expertise in nucleic acid-based products is helping to enable Intellia's groundbreaking genome editing capabilities.”
Since the launch of TriLink’s CleanCap® analog in 2017, its technology continues to advance the mRNA manufacturing industry and has even been used in two of the first commercially approved COVID-19 vaccines. TriLink’s CleanCap M6™ is its most robust cap analog to date, with studies indicating increased mRNA expression by 30% or more versus enzymatic capping methods, and reduced manufacturing costs by 20-40%.*
*Data and customer insights garnered from a market assessment conducted by a third-party consulting firm on behalf of TriLink in November 2022.
About TriLink BioTechnologies TriLink BioTechnologies, a Maravai LifeSciences company, is helping to realize the power and potential of mRNA. As a global leader in nucleic acid and mRNA solutions for more than 25 years. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its proprietary CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com
Released November 1, 2023